| saxagliptin vs | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs glipizide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.00 [0.89 1.12] | p=1.00 | 0 | 16492 | 1 | SAVOR-TIMI 53, | | Cardiovascular death | 1.03 [0.86 1.22] | p=1.00 | 0 | 16492 | 1 | SAVOR-TIMI 53, | | myocardial infarction (fatal and non fatal) | 0.95 [0.80 1.12] | p=1.00 | 0 | 16492 | 1 | SAVOR-TIMI 53, | | stroke (fatal and non fatal) | 1.10 [0.88 1.39] | p=1.00 | 0 | 16492 | 1 | SAVOR-TIMI 53, | | All cause death | 1.10 [0.96 1.27] | p=1.00 | 0 | 16492 | 1 | SAVOR-TIMI 53, | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs placebo (add on current treatment) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs placebo (add on insulin) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs placebo (add on TZD) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs placebo (monotherapy) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs sitagliptin (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin + glyburide vs glyburide uptitration | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin plus metformin XR 1500mg vs metformin up to 2000mg | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All types of patients: 25 trials - DeFronzo - saxgliptin, renal study - saxagliptin - saxagliptin vs sitagliptin - Rosenstock - CV181-011 - CV181-038 - Jadzinsky - CV181-057 - CV181-066 - CV181-080 - CV181-085 - Hollander - CV181-040 - CV181-041 - Kawamori - Forst - Fonseca - SAVOR-TIMI 53 - Nowicki - Yang - Nowicki - Göke - Scheen - Stenlöf
| saxagliptin vs | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs glipizide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.00 [0.89 1.12] | p=1.00 | 0 | 16492 | 1 | SAVOR-TIMI 53, | | Cardiovascular death | 1.03 [0.86 1.22] | p=1.00 | 0 | 16492 | 1 | SAVOR-TIMI 53, | | myocardial infarction (fatal and non fatal) | 0.95 [0.80 1.12] | p=1.00 | 0 | 16492 | 1 | SAVOR-TIMI 53, | | stroke (fatal and non fatal) | 1.10 [0.88 1.39] | p=1.00 | 0 | 16492 | 1 | SAVOR-TIMI 53, | | All cause death | 1.10 [0.96 1.27] | p=1.00 | 0 | 16492 | 1 | SAVOR-TIMI 53, | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs placebo (add on current treatment) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs placebo (add on insulin) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs placebo (add on TZD) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs placebo (monotherapy) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs sitagliptin (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin + glyburide vs glyburide uptitration | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin plus metformin XR 1500mg vs metformin up to 2000mg | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Drug naïve patients: 4 trials - Rosenstock - CV181-011 - CV181-038 - CV181-041
| saxagliptin vs placebo (monotherapy) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
In patients inadequately controlled on standard therapy: 1 trials - saxgliptin, renal study
| saxagliptin vs placebo (add on current treatment) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on metformin: 3 trials - DeFronzo - saxagliptin vs sitagliptin - CV181-080
| saxagliptin vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs sitagliptin (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on monotherapy : 6 trials - DeFronzo - saxagliptin vs sitagliptin - Jadzinsky - CV181-066 - CV181-080 - Hollander
| saxagliptin vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs placebo (add on TZD) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| saxagliptin vs sitagliptin (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on TZD: 1 trials - Hollander
| saxagliptin vs placebo (add on TZD) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled with insulin: 1 trials - CV181-057
| saxagliptin vs placebo (add on insulin) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
